Your browser doesn't support javascript.
loading
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).
Speranza, Desirèe; Sapuppo, Elena; Aprile, Giuseppe; Auriemma, Alessandra; Bergamo, Francesca; Bianco, Roberto; Bordonaro, Roberto; Brandi, Giovanni; Brunetti, Oronzo; Carnaghi, Carlo; Ciliberto, Domenico; Cinieri, Saverio; Corallo, Salvatore; De Vita, Ferdinando; Di Donato, Samantha; Ferraù, Francesco; Fornaro, Lorenzo; Barucca, Viola; Giommoni, Elisa; Lotesoriere, Claudio; Luchini, Claudio; Masini, Cristina; Niger, Monica; Pisconti, Salvatore; Rapposelli, Ilario Giovanni; Rimassa, Lorenza; Rognone, Chiara; Rodriquenz, Maria Grazia; Corsini, Lidia Rita; Santin, Daniele; Scarpa, Aldo; Scartozzi, Mario; Soto Parra, Hector; Tonini, Giuseppe; Tortora, Giampaolo; Tralongo, Paolo; Silvestris, Nicola.
Affiliation
  • Speranza D; Medical Oncology Unit, Department of Human Pathology G. Barresi, University of Messina, Messina, Sicily, Italy.
  • Sapuppo E; Medical Oncology Unit, Department of Human Pathology G. Barresi, University of Messina, Messina, Sicily, Italy.
  • Aprile G; Department of Oncology, San Bortolo General Hospital, ULSS 8 Berica-Vicenza, Vicenza, Veneto, Italy.
  • Auriemma A; Medical Oncology Section, Department of Medicine, University of Verona, Verona, Veneto, Italy.
  • Bergamo F; Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Veneto, Italy.
  • Bianco R; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Campania, Italy.
  • Bordonaro R; Medical Oncology Unit, ARNAS Garibaldi, Catania, Sicily, Italy.
  • Brandi G; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Emilia-Romagna, Italy.
  • Brunetti O; Alma Mater Studiorum - University of Bologna - Department of Medical and Surgical Sciences, Bologna, Emilia-Romagna, Italy.
  • Carnaghi C; Medical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Apulia, Italy.
  • Ciliberto D; Clinical Trials Unit, Istituto Clinico Humanitas, Centro Catanese di Oncologia, Catania, Sicily, Italy.
  • Cinieri S; University Magna Græcia of Catanzaro, Catanzaro, Calabria, Italy.
  • Corallo S; Medical Oncology Unit, Ospedale di Summa A. Perrino, Brindisi, Apulia, Italy.
  • De Vita F; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy.
  • Di Donato S; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania Luigi Vanvitelli, Naples, Campania, Italy.
  • Ferraù F; Medical Oncology Department ASL Toscana Centro, Santo Stefano Hospital Prato.
  • Fornaro L; St. Vincent Hospital, Division of Medical Oncology, Taormina, Messina, Sicily, Italy.
  • Barucca V; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Tuscany, Italy.
  • Giommoni E; UOC Oncologia, Azienda Ospedaliera San Camillo- Forlanini, Roma, Lazio, Italy.
  • Lotesoriere C; Medical Oncology Unit, Careggi University Hospital, Florence, Tuscany, Italy.
  • Luchini C; Oncology Unit of National Institute of Gastroenterology - IRCCS Saverio de Bellis, Research Hospital Castellana Grotte, Bari, Apulia, Italy.
  • Masini C; Department of Diagnostics and Public Health, Section of Pathology, and ARC-Net Research Center, University and Hospital Trust of Verona, Verona, Veneto, Italy.
  • Niger M; Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy.
  • Pisconti S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardy, Italy.
  • Rapposelli IG; Unit of Medical Oncology, Ospedale S.G. Moscati, Taranto, Apulia, Italy.
  • Rimassa L; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Emilia-Romagna, Italy.
  • Rognone C; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Lombardy, Italy.
  • Rodriquenz MG; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Lombardy, Italy.
  • Corsini LR; Department of Oncology, University of Turin, AO Ordine Mauriziano Hospital, Turin, Italy.
  • Santin D; Oncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • Scarpa A; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Sicily, Italy.
  • Scartozzi M; Oncology Unit (UOC) Oncologia A, Department of Radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, Lazio, Italy.
  • Soto Parra H; Department of Diagnostics and Public Health, Section of Pathology, and ARC-Net Research Center, University and Hospital Trust of Verona, Verona, Veneto, Italy.
  • Tonini G; Medical Oncology, University and University Hospital, Cagliari, Sardinia, Italy.
  • Tortora G; Department of Oncology, Medical Oncology, University Hospital Policlinico-San Marco, Catania, Sicily, Italy.
  • Tralongo P; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Lazio, Italy.
  • Silvestris N; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Lazio, Italy.
Tumori ; 110(3): 203-208, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38326240
ABSTRACT

INTRODUCTION:

About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants?Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected.

METHODS:

An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers.Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes.

CONCLUSIONS:

We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biliary Tract Neoplasms / Cholangiocarcinoma Type of study: Clinical_trials / Observational_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Tumori Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biliary Tract Neoplasms / Cholangiocarcinoma Type of study: Clinical_trials / Observational_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Tumori Year: 2024 Document type: Article Affiliation country: Country of publication: